For secondary prevention of coronary heart disease in patients under 75, which statin regimen is recommended?

For secondary prevention of coronary heart disease in patients under 75, which statin regimen is recommended?

• A. High-intensity statin: atorvastatin 40-80 mg or rosuvastatin 20-40 mg
• B. Moderate-intensity statin: simvastatin 40 mg
• C. Low-dose statin
• D. No statin

Answer: (A)

Maximizing LDL reduction with high-intensity statin therapy is the recommended approach for secondary prevention of coronary heart disease in patients under 75. For established ASCVD, guidelines aim for at least a 50% drop in LDL cholesterol to achieve the greatest reduction in recurrent events. Regimens such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg reliably achieve that level of LDL lowering and have the strongest evidence for reducing myocardial infarction, stroke, and death in this setting. Moderate- or low-intensity statins lower LDL less and thus offer less protection against future events, which is why they’re not preferred here. If a patient cannot tolerate high-intensity statins, alternatives like ezetimibe or PCSK9 inhibitors can be considered, but the first-line choice is high-intensity statin therapy. Regular monitoring and evaluation for side effects or interactions help ensure safety while aiming for the target LDL reduction.

Maximizing LDL reduction with high-intensity statin therapy is the recommended approach for secondary prevention of coronary heart disease in patients under 75. For established ASCVD, guidelines aim for at least a 50% drop in LDL cholesterol to achieve the greatest reduction in recurrent events. Regimens such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg reliably achieve that level of LDL lowering and have the strongest evidence for reducing myocardial infarction, stroke, and death in this setting. Moderate- or low-intensity statins lower LDL less and thus offer less protection against future events, which is why they’re not preferred here. If a patient cannot tolerate high-intensity statins, alternatives like ezetimibe or PCSK9 inhibitors can be considered, but the first-line choice is high-intensity statin therapy. Regular monitoring and evaluation for side effects or interactions help ensure safety while aiming for the target LDL reduction.